News
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)
Jaguar Health's crofelemer shows promise in treating pediatric intestinal failure patients with MVID and SBS. Positive results presented at ESPGHAN conference -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders
Jaguar Health, Inc. announces voting results of Special Meeting of Stockholders with five approved proposals for novel prescription drugs derived from plants for GI and mental health indications -
-
-
COMMUNIQUÉ DE PRESSE
Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs
Jaguar Health plans to utilize AI platforms to enhance the development and commercialization of crofelemer for intestinal failure treatment, targeting ultrarare pediatric disorder MVID -
